S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Apellis Pharmaceuticals (APLS) Short Interest Ratio & Short Volume

$47.53
+0.02 (+0.04%)
(As of 04/19/2024 ET)

Apellis Pharmaceuticals Short Interest Data

Current Short Volume
10,440,000 shares
Previous Short Volume
10,590,000 shares
Change Vs. Previous Month
-1.42%
Dollar Volume Sold Short
$613.66 million
Short Interest Ratio / Days to Cover
7.1
Last Record Date
March 31, 2024
Outstanding Shares
120,580,000 shares
Percentage of Shares Shorted
8.66%
Today's Trading Volume
1,179,340 shares
Average Trading Volume
1,132,779 shares
Today's Volume Vs. Average
104%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Apellis Pharmaceuticals ?

Sign up to receive the latest short interest report for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

APLS Short Interest Over Time

APLS Days to Cover Over Time

APLS Percentage of Float Shorted Over Time

Apellis Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/31/202410,440,000 shares $613.66 million -1.4%N/A7.1 $58.78
3/15/202410,590,000 shares $600.88 million +5.3%N/A6.7 $56.74
2/29/202410,060,000 shares $623.42 million -2.0%N/A5.1 $61.97
2/15/202410,270,000 shares $694.05 million -3.8%N/A4.9 $67.58
1/31/202410,670,000 shares $675.30 million -11.3%N/A5.1 $63.29
1/15/202412,030,000 shares $844.87 million +2.9%N/A5.4 $70.23
12/31/202311,690,000 shares $699.76 million -9.9%N/A5.1 $59.86
12/15/202312,980,000 shares $683.79 million -14.9%N/A5.2 $52.68
11/30/202315,260,000 shares $822.06 million -5.5%N/A6.4 $53.87
11/15/202316,140,000 shares $781.18 million -0.6%N/A6.9 $48.40
10/31/202316,230,000 shares $789.75 million -12.7%N/A5.2 $48.66
10/15/202318,590,000 shares $900.50 million +10.9%N/A4.5 $48.44
9/30/202316,770,000 shares $637.93 million +23.2%N/A3.3 $38.04
9/15/202313,610,000 shares $604.83 million +10.6%N/A2.9 $44.44
8/31/202312,310,000 shares $519.61 million -10.5%N/A2.7 $42.21
8/15/202313,750,000 shares $449.90 million +43.2%N/A3.1 $32.72
7/31/20239,600,000 shares $247.20 million +1.3%N/A2.6 $25.75
7/15/20239,480,000 shares $801.06 million -1.2%N/A3.5 $84.50
6/30/20239,590,000 shares $873.65 million -16.3%N/A6 $91.10
6/15/202311,460,000 shares $1.03 billion +0.9%N/A6.7 $89.60
5/31/202311,360,000 shares $975.26 million +3.3%N/A7 $85.85
5/15/202311,000,000 shares $969.21 million +7.0%N/A5.6 $88.11
4/30/202310,280,000 shares $857.66 million -16.6%N/A5.4 $83.43
4/15/202312,330,000 shares $998.11 million +0.4%N/A6.7 $80.95
3/31/202312,280,000 shares $809.99 million +1.1%N/A7.1 $65.96
3/15/202312,150,000 shares $796.19 million +13.1%N/A7.6 $65.53
2/28/202310,740,000 shares $703.26 million +18.5%N/A7.4 $65.48
2/15/20239,060,000 shares $479.82 million -0.6%N/A6.5 $52.96
1/31/20239,110,000 shares $480.37 million -5.0%N/A6.9 $52.73
1/15/20239,590,000 shares $504.05 million +4.6%N/A7.4 $52.56
12/30/20229,170,000 shares $474.18 million -8.8%N/A7.1 $51.71
12/15/202210,050,000 shares $526.72 million +1.9%N/A6.9 $52.41
11/30/20229,860,000 shares $492.31 million -5.1%N/A6.6 $49.93
11/15/202210,390,000 shares $484.28 million +6.8%N/A6.3 $46.61
10/31/20229,730,000 shares $588.57 million +10.8%N/A6.6 $60.49
10/15/20228,780,000 shares $499.93 million -10.6%N/A6.4 $56.94
9/30/20229,820,000 shares $670.71 million +7.9%N/A6.8 $68.30
9/15/20229,100,000 shares $589.23 million +8.6%N/A6.9 $64.75
8/31/20228,380,000 shares $507.07 million +4.9%N/A6.5 $60.51
8/15/20227,990,000 shares $548.43 million -18.8%N/A7.4 $68.64
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

APLS Short Interest - Frequently Asked Questions

What is Apellis Pharmaceuticals' current short interest?

Short interest is the volume of Apellis Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 10,440,000 shares of APLS short. Learn More on Apellis Pharmaceuticals' current short interest.

What is a good short interest ratio for Apellis Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APLS shares currently have a short interest ratio of 7.0. Learn More on Apellis Pharmaceuticals's short interest ratio.

Which institutional investors are shorting Apellis Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Apellis Pharmaceuticals: Portman Square Capital LLP, Perceptive Advisors LLC, GTS Securities LLC, Wolverine Trading LLC, Parallax Volatility Advisers L.P., Citadel Advisors LLC, TIG Advisors LLC, Cubist Systematic Strategies LLC, Harvest Management LLC, Capital Fund Management S.A., Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Apellis Pharmaceuticals' short interest increasing or decreasing?

Apellis Pharmaceuticals saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 10,440,000 shares, a decline of 1.4% from the previous total of 10,590,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Apellis Pharmaceuticals' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Apellis Pharmaceuticals: Ionis Pharmaceuticals, Inc. (7.11%), Elanco Animal Health Incorporated (2.53%), Jazz Pharmaceuticals plc (5.41%), Cytokinetics, Incorporated (13.33%), Blueprint Medicines Co. (7.14%), Viking Therapeutics, Inc. (8.64%), Cerevel Therapeutics Holdings, Inc. (11.06%), Intra-Cellular Therapies, Inc. (3.58%), Madrigal Pharmaceuticals, Inc. (16.88%), Organon & Co. (4.28%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

What does it mean to sell short Apellis Pharmaceuticals stock?

Short selling APLS is an investing strategy that aims to generate trading profit from Apellis Pharmaceuticals as its price is falling. APLS shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Apellis Pharmaceuticals?

A short squeeze for Apellis Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of APLS, which in turn drives the price of the stock up even further.

How often is Apellis Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLS, twice per month. The most recent reporting period available is March, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:APLS) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners